GLP1R and diabetes mellitus: Our data suggest that the GLP-1 receptor agonist lixisenatide has a protective effect on the microvasculature of the diabetic retina, most likely due to a combination of neuroprotective and antioxidative effects of lixisenatide on the neurovascular unit.